OKYO Pharma Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMMLF research report →
Price Chart
About the company
OKYO Pharma Limited is an early-stage biopharmaceutical company focused on developing therapies for individuals experiencing inflammatory eye conditions and ocular pain. A key asset in their pipeline is OK-101, specifically aimed at treating dry eye disease. Additionally, the company is advancing OK-201, which is a preclinical lipidated-peptide analogue sourced from bovine adrenal medulla, intended for the management of neuropathic ocular pain.
- CEO
- Gary S. Jacob
- IPO
- 2020
- Employees
- 7
- HQ
- London, GB
Get TickerSpark's AI analysis on EMMLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.73M
- P/E
- -5.81
- PEG
- 0.05
- P/S
- 0.00
- P/B
- 4.21
- EV/EBITDA
- -4.21
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -200.67%
- ROIC
- -74.59%
- 52W High
- $0.89
- 52W Low
- $0.01
- 50D MA
- $0.04
- 200D MA
- $0.03
- Beta
- -0.06
- RSI (14)
- 99
- Avg Volume
- 390
No earnings-call transcripts are available for EMMLF yet.
- Free Float
- 0.5%
- Shares Outstanding
- 1.66B
- Float Shares
- 8.54M
Our EMMLF coverage
Recent articles, reports, and earnings notes.
No research on EMMLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EMMLF report →Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
investorplace.com · Aug 1
OKYO Pharma inks collaboration with Tufts Medical Center
proactiveinvestors.com · Jul 28
OKYO Pharma begins OK-101 phase 2 dosing
proactiveinvestors.co.uk · Jun 6
OKYO Pharma to address key conference with data on dry eye drug
proactiveinvestors.co.uk · May 3
OKYO Pharma screens first patient for dry eye disease trial
proactiveinvestors.co.uk · May 2
OKYO Pharma ready to kick off dry eye trial in the US
proactiveinvestors.co.uk · Apr 25
OKYO Pharma plans UK de-listing in favour of US quote
proactiveinvestors.co.uk · Apr 4
OKYO Pharma shares soar on news it is gearing up for dry eye disease treatment trial
proactiveinvestors.co.uk · Mar 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.